Indoco Remedies Limited
National Stock Exchange of IndiaTotal Valuation
Indoco Remedies Limited carries a market capitalization of 19.12B, placing it among publicly traded companies globally. Its enterprise value stands at 24.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 19.12B |
| Enterprise Value | 24.61B |
Share Statistics
Indoco Remedies Limited currently has 92.17M shares outstanding.
| Shares Outstanding | 92.17M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.80, and the price-to-book ratio stands at 77.17.
| PE Ratio | N/A |
| PS Ratio | 0.80 |
| PB Ratio | 77.17 |
| P/TBV Ratio | 1.95 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Indoco Remedies Limited trades at an EV/EBITDA multiple of 160.34 and an EV/FCF ratio of 21.73. The EV/Sales ratio of 1.37 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 160.34 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.37 |
| EV / EBITDA | 160.34 |
| EV / EBIT | 160.34 |
| EV / FCF | 21.73 |
Financial Position
Indoco Remedies Limited maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.91, indicating elevated leverage, while an interest coverage ratio of 0.13 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.13 |
| Quick Ratio | 0.04 |
| Debt / Equity | 116.91 |
| Debt / EBITDA | 70.99 |
| Interest Coverage | 0.13 |
Financial Efficiency
| Return on Equity (ROE) | -26.84 |
| Return on Assets (ROA) | -3.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | -78.10M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Indoco Remedies Limited's stock has declined approximately -25.67897% over the past 52 weeks. The 50-day moving average sits at 206.49, while the 200-day moving average is 235.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -25.67897% |
| 50-Day Moving Average | 206.49 |
| 200-Day Moving Average | 235.71 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Indoco Remedies Limited generated 17.91B in revenue and converted that into -951.50M in net income, yielding earnings per share of -11.36. EBITDA reached 153.50M, while operating income came in at 153.50M.
| Revenue | 17.91B |
| Gross Profit | 12.49B |
| Operating Income | 153.50M |
| Pretax Income | -1.06B |
| Net Income | -951.50M |
| EBITDA | 153.50M |
| EBIT | 153.50M |
| Earnings Per Share (EPS) | -11.36 |
Balance Sheet
Indoco Remedies Limited holds 458.40M in cash and equivalents against 10.90B in total debt, resulting in a net debt position of 10.10B. Total book value stands at 184.60M, with working capital of 1.41B providing operational flexibility.
| Cash & Cash Equivalents | 458.40M |
| Total Debt | 10.90B |
| Net Debt | 10.10B |
| Equity (Book Value) | 184.60M |
| Book Value Per Share | 2.13 |
| Working Capital | 1.41B |
Margins
Indoco Remedies Limited operates with a gross margin of 69.75, reflecting its pricing power and cost economics. The operating margin of 0.86 and net profit margin of -5.31 provide insight into operational efficiency.
| Gross Margin | 69.75 |
| Operating Margin | 0.86 |
| Pretax Margin | -5.95 |
| Profit Margin | -5.31 |
| EBITDA Margin | 0.86 |
Stock Splits
Indoco Remedies Limited's most recent stock split took place on May 17, 2012 with a 1:5 split ratio.
| Last Split Date | 5/17/2012 |
| Split Ratio | 1:5 |
Scores
Indoco Remedies Limited posts an Altman Z-Score of 1.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.36 |